GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 166 filers reported holding GENMARK DIAGNOSTICS INC in Q3 2020. The put-call ratio across all filers is 3.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,050,000 | -61.4% | 43,953 | -76.4% | 0.08% | -59.2% |
| Q4 2020 | $2,721,000 | +28.0% | 186,371 | +24.5% | 0.18% | +31.4% |
| Q3 2020 | $2,126,000 | -26.4% | 149,717 | -23.7% | 0.14% | -28.6% |
| Q2 2020 | $2,887,000 | +1171.8% | 196,240 | +256.2% | 0.20% | +988.9% |
| Q1 2020 | $227,000 | +11.3% | 55,100 | +29.6% | 0.02% | +38.5% |
| Q4 2019 | $204,000 | -6.4% | 42,500 | +18.1% | 0.01% | 0.0% |
| Q3 2019 | $218,000 | -6.8% | 36,000 | 0.0% | 0.01% | -7.1% |
| Q2 2019 | $234,000 | -8.2% | 36,000 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $255,000 | +15.4% | 36,000 | -20.7% | 0.01% | +16.7% |
| Q4 2018 | $221,000 | -14.3% | 45,400 | +29.3% | 0.01% | +9.1% |
| Q3 2018 | $258,000 | +10.7% | 35,121 | +18.8% | 0.01% | +120.0% |
| Q3 2015 | $233,000 | +65.2% | 29,569 | +117.4% | 0.01% | +25.0% |
| Q2 2013 | $141,000 | – | 13,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 950,000 | $9,823,000 | 1.01% |
| Curi RMB Capital, LLC | 939,265 | $9,720,000 | 0.74% |
| KOPP INVESTMENT ADVISORS LLC | 96,384 | $997,000 | 0.39% |
| Alyeska Investment Group, L.P. | 314,502 | $3,254,000 | 0.16% |
| PFM Health Sciences, LP | 604,199 | $6,252,000 | 0.13% |
| Spark Investment Management LLC | 47,000 | $485,000 | 0.13% |
| ELLINGTON MANAGEMENT GROUP LLC | 61,700 | $638,000 | 0.12% |
| PUTNAM INVESTMENTS LLC | 1,745,494 | $18,048,000 | 0.05% |
| PointState Capital LP | 298,976 | $3,094,000 | 0.05% |
| Partner Investment Management, L.P. | 20,717 | $214,000 | 0.05% |